title: [Use of recombinant Human Growth Hormone (rHGH)].
abstract: Recombinant human growth hormone, synthesized in E.coli or mammalian cells cultures, is since 1985, a useful therapeutic resource to increase growth velocity and final height. In this paper are discussed the four phases (aims, security and efficacy, utility and efficiency) indispensables to define the start of treatment, as well as the absolute, relative and metabolic indications and the transitory and permanent conditions that contraindicate its use. It is commented the way to optimize the results (simple but indispensables indications for the physician, the patients and their family). Finally it is analyzed the results of treatment in patients with growth hormone deficiency, Turner syndrome, chronic renal failure, Prader-Willi syndrome, Noonan syndrome, SHOX deficiency, intrauterine growth retardation and idiopathic short stature.
authors.affiliation: Servicio de Endocrinología, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México, México. raulcalzada@yahoo.com.
authors.forename: Raúl
authors.initials: R
authors.lastname: Calzada-León
mesh_terms: D000075203:Contraindications, Drug; D004334:Drug Administration Schedule; D004392:Dwarfism / Q000188:drug therapy; D005317:Fetal Growth Retardation / Q000188:drug therapy; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology; D019382:Human Growth Hormone / Q000009:adverse effects / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D009634:Noonan Syndrome / Q000188:drug therapy; D011218:Prader-Willi Syndrome / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy; D016896:Treatment Outcome; D014424:Turner Syndrome / Q000188:drug therapy
chemical_list: D011994:Recombinant Proteins; D019382:Human Growth Hormone
keywords: Hormones, hormone substitutes and hormone antagonists; Human growth hormone; Pituitary gonadotropins ; Recombinant proteins